Tranylcypromine/trifluoperazine

{{Short description|Combination drug}}

{{Drugbox

| image =

| width =

| caption =

| type = combo

| drug_name = Tranylcypromine/trifluoperaizne

| component1 = Tranylcypromine

| class1 = Monoamine oxidase inhibitor

| component2 = Trifluoperazine

| class2 = Typical antipsychotic

| tradename = Parstelin, Parmodalin, Jatrosom N, Stelapar

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Rx-only

| routes_of_administration = Oral

| CAS_number = 60108-71-6

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

}}

Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.{{cite book| vauthors = Dart RC | chapter = Monoamine Oxidase Inhibitors |title=Medical Toxicology| chapter-url = https://books.google.com/books?id=BfdighlyGiwC&pg=PA825 |year=2004 |publisher=Lippincott Williams & Wilkins |isbn=978-0-7817-2845-4 |pages=825–}}{{cite book | vauthors = Stahl SM |title=Prescriber's Guide: Stahl's Essential Psychopharmacology|url=https://books.google.com/books?id=Q7hkAwAAQBAJ&pg=PA783|date=15 May 2014|publisher=Cambridge University Press|isbn=978-1-107-67502-5|pages=783–}}{{cite journal | vauthors = Straker M, Grauer H | title = Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill | journal = Canadian Medical Association Journal | volume = 85 | issue = 3 | pages = 127–130 | date = July 1961 | pmid = 20326829 | pmc = 1848140 }} It contains 10 mg tranylcypromine and 1 mg trifluoperazine.{{cite book| vauthors = Kalinowsky LB, Hippius H, Klein HE |title=Biological Treatments in Psychiatry|url=https://books.google.com/books?id=UM9rAAAAMAAJ|year=1982|publisher=Grune and Stratton, Harcourt Brace Jovanovich|isbn=978-0-8089-1423-5}} The drug has been in clinical use since at least 1961.

It may come to assume a certain place in the treatment of borderline personality disorder.Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of general psychiatry, 45(2), 111–119. https://doi.org/10.1001/archpsyc.1988.01800260015002